Literature DB >> 17280764

Ultrasonic assessment of hepatic blood flow as a marker of mouse hepatocarcinoma.

Philippe Bonnin1, Aude Villemain, François Vincent, Haythem Debbabi, Jean Sébastien Silvestre, Jean Olivier Contreres, Bernard I Levy, Gérard Tobelem, Evelyne Dupuy.   

Abstract

Two-dimensional color-coded pulsed Doppler ultrasonography (US) with a 12-MHz linear transducer was used to follow tumor growth and neoangiogenesis development in 12 transgenic mice developing a whole liver hepatocellular carcinoma (HCC) induced by the expression of SV40-T antigen. In this model, male mice developed HCC at various temporal and histologic stages (hyperplastic, four-eight wk; nodular, 12 wk; diffuse carcinoma, 16-20 wk), whereas female mice remained tumor free. Seven age-matched tumor-free mice were used as controls. Liver volume was calculated from B-mode images of the abdomen. Blood flow waveforms were recorded from the hepatic tumor-feeding artery upstream from the tumor vessels, allowing quantitative blood flow velocity measurements. Measurements were performed every four weeks from four to 20 weeks. As early as the hyperplastic stage (eight weeks), liver volume was increased by 2.7-fold, hepatic artery peak-systolic blood flow velocities (BFV) by 1.5-fold, end-diastolic BFV by 1.6-fold and mean BFV by 2.0-fold compared with control values (p < 0.001). Differences increased until 20 weeks and peak-systolic reached 90 +/- 6, end-diastolic 54 +/- 5 and mean BFV 48 +/- 5 cm s(-1). Successive measurements of BFV were reproducible and intraobserver repeatability coefficient values were <3 cm s(-1). In contrast, mesenteric artery BFV, which did not supply tumor region, did not show any significant difference with respect to control values. Thus, an increase in BFV constitutes a functional evaluation of tumor vascularity. In preclinical studies in small animals, measurements of liver volume and blood flow velocities in hepatic tumor-feeding artery provide a useful, reproducible, noninvasive, easy-to-repeat tool to monitor tumor growth and neoangiogenesis in hepatocellular carcinoma in mice.

Entities:  

Mesh:

Year:  2007        PMID: 17280764     DOI: 10.1016/j.ultrasmedbio.2006.09.010

Source DB:  PubMed          Journal:  Ultrasound Med Biol        ISSN: 0301-5629            Impact factor:   2.998


  5 in total

1.  Small interfering RNAs induce target-independent inhibition of tumor growth and vasculature remodeling in a mouse model of hepatocellular carcinoma.

Authors:  Mathieu Bergé; Philippe Bonnin; Eric Sulpice; José Vilar; David Allanic; Jean-Sébastien Silvestre; Bernard I Lévy; Gordon C Tucker; Gérard Tobelem; Tatyana Merkulova-Rainon
Journal:  Am J Pathol       Date:  2010-10-22       Impact factor: 4.307

Review 2.  Doppler velocity measurements from large and small arteries of mice.

Authors:  Craig J Hartley; Anilkumar K Reddy; Sridhar Madala; Mark L Entman; Lloyd H Michael; George E Taffet
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-05-13       Impact factor: 4.733

3.  Rosuvastatin counteracts vessel arterialisation and sinusoid capillarisation, reduces tumour growth, and prolongs survival in murine hepatocellular carcinoma.

Authors:  Annemilaï Tijeras-Raballand; Patricia Hainaud-Hakim; Jean-Olivier Contreres; Caroline Gest; Carole Le Henaff; Bernard I Levy; Marc Pocard; Claudine Soria; Evelyne Dupuy
Journal:  Gastroenterol Res Pract       Date:  2011-02-22       Impact factor: 2.260

4.  Preoperative color Doppler ultrasonography predicts early recurrence in AFP-positive hepatocellular carcinoma.

Authors:  Miao Chen; Duo Wang; Yuan Zhao; Dan-Mei Lu; Hong-Xue Li; Jun-Jie Liu; Hang Li
Journal:  Oncol Lett       Date:  2019-09-09       Impact factor: 2.967

5.  MRI-guided interventional natural killer cell delivery for liver tumor treatment.

Authors:  Zhanliang Su; Xifu Wang; Linfeng Zheng; Tianchu Lyu; Matteo Figini; Bin Wang; Daniel Procissi; Junjie Shangguan; Chong Sun; Liang Pan; Lei Qin; Bin Zhang; Yury Velichko; Riad Salem; Vahid Yaghmai; Andrew C Larson; Zhuoli Zhang
Journal:  Cancer Med       Date:  2018-03-30       Impact factor: 4.452

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.